When examining 25 years of pharmaceutical sales data in the United States, a clear picture emerges: a handful of drugs have generated tens of billions of dollars in revenue, reshaping the industry and transforming how we understand drug development, patent strategy, and clinical research. Using data from IQVIA, the following list ranks the 10 best-selling drugs US markets produced between 1992 and 2017, measured by total revenue accumulated over that period. What drove their success goes beyond the drugs themselves.
Launch timing, demonstrated clinical need, scientific differentiation, and sustained marketing efforts all played a decisive role. The best-selling drugs US history has recorded share one common foundation: rigorous clinical trial development that proved their value before they ever reached patients.
Understanding which drugs became blockbusters and why also matters for clinical research organizations like FOMAT. Each of the drugs on this list passed through rigorous Phase I through Phase IV clinical trials before reaching patients. Their stories reflect what well-executed research can ultimately produce.
How the best-selling drugs US markets ranked over 25 years
The ranking below is based on cumulative US revenue from 1992 to 2017, compiled by IQVIA, one of the most authoritative sources of pharmaceutical market data. The list spans multiple therapeutic categories including cardiovascular disease, immunology, respiratory conditions, oncology support, and mental health. Some of these drugs are now off patent and available as generics or biosimilars. Others continue to generate significant revenue even decades after their initial approval.
Lipitor: the all-time leader among best-selling drugs in the US
Pfizer’s Lipitor holds the top position with $94.67 billion in cumulative US sales. Originally developed by Warner-Lambert and approved by the FDA in late 1996, Lipitor was not the first statin to reach the market, yet it became the most commercially successful one in history. Its rise was fueled by large scale clinical studies that demonstrated its ability to reduce not just cholesterol levels but also the incidence of heart attacks. As noted by the Mayo Clinic, statins as a drug class have become one of the most widely prescribed treatments for reducing cardiovascular risk.
Growing public awareness around cardiovascular risk, combined with Pfizer’s marketing strength and the FDA’s 1997 relaxation of direct to consumer advertising rules, helped elevate Lipitor to dominance. Although sales declined sharply following patent expiration in late 2011, the drug still generated $1.92 billion in 2017 revenue.
Humira: the new king of best-selling drugs US pharma has ever seen
AbbVie’s Humira follows with $75.72 billion in cumulative US sales, making it the clear successor to Lipitor’s throne. Approved on the last day of 2002, it was the first fully human monoclonal antibody to reach patients, initially for rheumatoid arthritis. Two competing TNF-alpha inhibitors, Enbrel and Remicade, had already been on the market for over four years at that point.
Humira distinguished itself through a more convenient self-injection format versus intravenous administration, as well as through an aggressive expansion of approved indications that came to include psoriatic arthritis, Crohn’s disease, and juvenile idiopathic arthritis.
Price increases over the years also contributed significantly to its revenue growth. FOMAT actively supports research in inflammatory and autoimmune conditions through its Phase II and III clinical trial capabilities.
Nexium, Advair, and the power of respiratory and digestive blockbusters
AstraZeneca’s Nexium, widely known as the purple pill, reached $72.45 billion in US sales over the same period. Approved in 2001 for gastroesophageal reflux disease, Nexium improved upon its predecessor Prilosec with higher healing rates in clinical trials, though the distinction between proton pump inhibitors remained a subject of debate. Before generic and over the counter versions arrived in 2015, Nexium was generating approximately $3 billion annually.
GlaxoSmithKline’s Advair came fourth with $69.08 billion. A combination of fluticasone and salmeterol designed to treat asthma and chronic obstructive pulmonary disease, Advair benefited from the technical complexity of its Diskus inhaler device, which delayed generic competition for years even after patent protection lapsed in 2010.
Immunology and autoimmune drugs dominate the middle of the list
Amgen’s Enbrel, the first TNF-alpha inhibitor approved by the FDA, reached $67.78 billion in US sales. Approved in 1998 for rheumatoid arthritis and later expanded to additional autoimmune conditions, Enbrel has remained a physician favorite despite the competition and generated $5.21 billion in US revenue in 2017 alone.
Johnson and Johnson’s Remicade, with $54.67 billion in cumulative sales, was among the earliest treatments for Crohn’s disease before expanding into rheumatoid arthritis and psoriatic arthritis. Its requirement for intravenous infusion put it at a disadvantage compared to self-administered alternatives, though aggressive payer agreements helped it maintain market share even after a biosimilar launched in 2016.
Epogen, Abilify, Neulasta, and Plavix round out the top 10
Amgen’s Epogen, approved in 1989 for kidney disease related anemia, accumulated $55.63 billion in US sales over the 25 year period. Its orphan drug status granted an extended exclusivity window, and legal protections delayed biosimilar competition until 2014.
Abilify, developed by Otsuka and co-marketed with Bristol-Myers Squibb, generated $51.34 billion with approvals spanning schizophrenia, bipolar disorder, major depression, and autism. It later evolved into Abilify Maintena, an injectable formulation, and Abilify MyCite, a digitally trackable version with an embedded sensor.
Amgen’s Neulasta, approved in 2001 to boost white blood cell counts in chemotherapy patients, reached $47.40 billion in cumulative US sales and generated $4.53 billion in 2017 alone, with roughly 87 percent of that revenue coming from the United States.
Plavix, the blood thinner co-marketed by Sanofi and Bristol-Myers Squibb, closed out the list with $46.48 billion. Approved in 1998, it became the standard of care for preventing heart attack and stroke and earned a place on the World Health Organization’s list of essential medicines.
When its patent expired in 2012, it marked a defining transition away from the era of mass market megablockbusters. Reviewing the full list of best-selling drugs US pharma produced over this era reveals how much patent strategy, pricing, and clinical data shaped commercial outcomes.
What clinical research makes possible
Every best-selling drug US patients have benefited from reached the market through a rigorous clinical development process. From early Phase I safety testing to large scale Phase III efficacy trials, the path from molecule to market depends entirely on well-designed, well-executed research.
FOMAT supports that process nationally, working with sponsors and CROs across Phase I through Phase IV clinical research capabilities to accelerate drug development while maintaining the scientific and regulatory standards that protect patients. The blockbuster drugs of the next 25 years are in development today, and clinical research is how they get there.